Fulgent Genetics, Inc. (FLGT) Financial Statements (2026 and earlier)

Company Profile

Business Address 4399 SANTA ANITA AVE
EL MONTE, CA 91731
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments336,077117,64187,88067,28155,14458,042
Cash and cash equivalent50,193117,64187,88067,28155,14458,042
Short-term investments285,884     
Receivables84,76271,18777,19071,47869,02157,315
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Other current assets22,55260,38458,61024,98526,44456,155
Other undisclosed current assets107,099258,162205,047253,040202,962155,027
Total current assets:550,490507,374428,727416,784353,571326,539
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization112,549111,865110,223107,077105,549106,810
Long-term investments and receivables369,269411,778484,471494,111570,351602,232
Long-term investments369,269411,778484,471494,111570,351602,232
Intangible asset, including goodwill, after accumulated amortization25,080160,335153,115155,064157,033159,170
Goodwill25,08025,08022,05522,05522,05522,055
Intangible asset, excluding goodwill, after accumulated amortization  135,255131,060133,009134,978137,115
Other noncurrent assets22,85623,21123,30232,70833,46039,012
Other undisclosed noncurrent assets133,281     
Total noncurrent assets:663,035707,189771,111788,960866,393907,224
TOTAL ASSETS:1,213,5251,214,5631,199,8381,205,7441,219,9641,233,763
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities52,71141,09840,58634,92742,64343,667
Accounts payable18,65418,08818,88718,23818,36419,805
Accrued liabilities34,05723,01021,69916,68924,27923,862
Deferred revenue3,6352,3092,6732,8172,2342,966
Debt836833830827810861
Other undisclosed current liabilities27,78528,18627,24627,34427,21226,496
Total current liabilities:84,96772,42671,33565,91572,89973,990
Noncurrent Liabilities
Long-term debt and lease obligation  91181271360448
Finance lease, liability  91181271360448
Liabilities, other than long-term debt14,56014,59712,02912,35913,34318,549
Deferred income tax liabilities6,9367,0406,1246,2376,3706,734
Other liabilities7,6247,5575,9056,1226,97311,815
Other undisclosed noncurrent liabilities7,2836,6924,6574,4294,2035,878
Total noncurrent liabilities:21,84321,38016,86717,05917,90624,875
Total liabilities:106,81093,80688,20282,97490,80598,865
Equity
Equity, attributable to parent1,111,9891,125,8881,116,5801,127,1781,133,2281,138,445
Common stock333333
Additional paid in capital574,520565,690550,599543,903543,126532,909
Accumulated other comprehensive income (loss)7,5126,8235,9984,335(368)9,178
Retained earnings529,954553,372559,980578,937590,467596,355
Equity, attributable to noncontrolling interest(5,274)(5,131)(4,944)(4,408)(4,069)(3,547)
Total equity:1,106,7151,120,7571,111,6361,122,7701,129,1591,134,898
TOTAL LIABILITIES AND EQUITY:1,213,5251,214,5631,199,8381,205,7441,219,9641,233,763

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues83,33684,06981,80373,46376,21471,743
Cost of revenue(50,754)(48,557)(47,368)(45,117)(44,365)(44,972)
Gross profit:32,58235,51234,43528,34631,84926,771
Operating expenses(68,820)(50,862)(54,148)(48,141)(47,984)(43,850)
Operating loss:(36,238)(15,350)(19,713)(19,795)(16,135)(17,079)
Nonoperating income (expense)6,9647,841(1,806)8,0728,090(1,453)
Investment income, nonoperating6,9367,8748,0918,0188,1238,090
Other nonoperating income (expense)44(5)46687544
Interest and debt expense(16)(28)(17)(14)(40)(14)
Loss from continuing operations before equity method investments, income taxes:(29,290)(7,537)(21,536)(11,737)(8,085)(18,546)
Other undisclosed income from continuing operations before income taxes162817144014
Loss from continuing operations before income taxes:(29,274)(7,509)(21,519)(11,723)(8,045)(18,532)
Income tax expense (benefit)5,6246832,263(176)1,8553,838
Net loss:(23,650)(6,826)(19,256)(11,899)(6,190)(14,694)
Net income attributable to noncontrolling interest23221829936930246
Net loss available to common stockholders, diluted:(23,418)(6,608)(18,957)(11,530)(5,888)(14,648)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(23,650)(6,826)(19,256)(11,899)(6,190)(14,694)
Other comprehensive income (loss) 8561,4264,733 10,255
Other undisclosed comprehensive income (loss) 778   (9,766) 
Comprehensive loss:(22,872)(5,970)(17,830)(7,166)(15,956)(4,439)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest143187536339522(154)
Comprehensive loss, net of tax, attributable to parent:(22,729)(5,783)(17,294)(6,827)(15,434)(4,593)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: